BRAF and melanoma: The IMspire150 trial showed that the addition of atezolizumab (anti–PD-L1) to vemurafenib and cobimetinib significantly improved PFS and overall survival in advanced BRAF-mutant melanoma, supporting the hypothesis that targeted therapies can enhance neoantigen release and improve immune checkpoint blockade efficacy [105,106,107,108,109].